LIVE WEBINAR: Wednesday, February 8, 2023, 5:00 PM – 6:00 PM Eastern Time

Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer

A CME/MOC-Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Wednesday, February 8th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Kathy D Miller, MD
Ballvé-Lantero Professor
Division of Hematology/Oncology
Associate Director for Clinical Research
The Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana

Ann Partridge, MD, MPH
Vice Chair of Medical Oncology
Director, Program for Young Women with Breast Cancer
Director, Adult Survivorship Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by an educational grant from TerSera Therapeutics LLC.

Wednesday, February 8, 2023
5:00 PM – 6:00 PM eastern time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • MODULE 1: Optimizing the Use of Ovarian Function Suppression (OFS)/Ablation in the Care of Patients with Breast Cancer
  • MODULE 2: Tolerability and Other Practical Issues with OFS, Including Its Potential Utility in Preserving Fertility

Target Audience
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, oncology nurses, general and breast surgeons and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the scientific rationale for ovarian function suppression/ablation as a therapeutic strategy for premenopausal patients with hormone-receptor (HR)-positive breast cancer, and appraise the risks and potential benefits of surgical and pharmacologic interventions.
  • Appraise clinical research findings documenting the efficacy of adding gonadotropin-releasing hormone agonists (GnRHa’s) to standard adjuvant endocrine therapy for localized HR-positive premenopausal breast cancer, and identify patients appropriate for this strategy.
  • Optimize the use of GnRHa therapy in the care of premenopausal women with HR-positive breast cancer, applying clinical research to guide the timing of initiation and duration of treatment.
  • Recognize the potential for chemotherapy-induced premature ovarian insufficiency with various cytotoxic agents used in breast cancer therapy, and assess the effectiveness and potential role of various interventions in preserving ovarian hormone production and facilitating successful childbirth.
  • Evaluate the side effects associated with GnRHa therapy in patients with breast cancer, and formulate supportive care strategies to minimize and manage these toxicities.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Partridge has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr MillerContracted Research: Astex Pharmaceuticals, Pfizer Inc, Radiopharm Theranostics (not yet active); Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Celcuity, Genentech, a member of the Roche Group, Merck.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from TerSera Therapeutics LLC.